Did you mean 6883 99m 0?
Displaying drugs 2001 - 2025 of 5983 in total
Tegoprazan
Tegoprazan (also known as CJ-12420) is a novel therapeutic developed by CJ Healthcare Corp for treating acid-related gastrointestinal diseases.[A234215, A234220] This drug is a potent and high-selective potassium-competitive acid blocker (P-CAB) with a fast onset of action and the ability to control gastric pH for a prolonged period of time.[A234215,...
Investigational
Glenzocimab
Investigational
North-methanocarbathymidine
Investigational
MRx-4DP0004
MRx-4DP0004 is a lyophilised formulation of the Bifidobacterium breve strain of commensal bacteria. It is a live biotherapeutic derived from the microbiota of a healthy human infant.
Investigational
Veligrotug
Veligrotug is under investigation in clinical trial NCT00791544 (Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma).
Investigational
Camoteskimab
Camoteskimab is under investigation in clinical trial NCT06436183 (A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis).
Investigational
PF-232798
PF-232798 is under investigation in clinical trial NCT01140425 (Study To Evaluate The Effect Of A Multiple Oral Dose Of PF-00232798 On QT Intervals In Healthy Subjects).
Investigational
Apc001PE
Investigational
Zanzalintinib
Investigational
LB-001
LB-001 is a gene editing therapy designed to incorporate a functioning version of the faulty methylmalonyl-COA mutase (MUT) gene into the genome of patients with methylmalonic acidemia.
Investigational
Iclepertin
Iclepertin is under investigation in clinical trial NCT05211947 (A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study).
Investigational
BMN-046
Experimental
Withdrawn
BMN-055
Experimental
Withdrawn
VAD-044
VAD-044 is an allosteric AKT inhibitor developed by Vaderis Therapeutics AG. It is being investigated for the treatment of Hereditary Hemorrhagic Telangiectasia.
Investigational
Iluzanebart
Investigational
Cendakimab
Cendakimab is a recombinant humanized anti-interleukin 13 (IL-13) monoclonal antibody.
Investigational
VK-0214
Investigational
Otlertuzumab
Otlertuzumab is under investigation in clinical trial NCT01188681 (Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia).
Investigational
Zorevunersen
Investigational
Ponezumab
Ponezumab is under investigation in clinical trial NCT00607308 (A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease).
Investigational
Mavodelpar
Investigational
CSIC002
CSIC002 is a small-molecule Sema-3A inhibitor. It is being investigated for the treatment of anterior ischemic optic neuropathy.
Investigational
Bepranemab
Bepranemab is a recombinant humanized Igg4P monoclonal antibody directed against human Tau.
Investigational
Porgaviximab
Investigational
Adriforant
Adriforant is under investigation in clinical trial NCT00992342 (A Phase 1 Study To Evaluate The Safety And Tolerability Of Different Doses Of PF-03893787 In Healthy Adult Volunteers).
Investigational
Displaying drugs 2001 - 2025 of 5983 in total